Medtronic has delivered four consecutive earnings beats on a foundation of near-perfect financial health metrics, but the stock is in a confirmed technical downtrend, options positioning signals unusual caution at a put/call ratio of roughly 5.7, and sole-source supplier dependencies represent a supply-chain vulnerability that limits conviction to add at current prices.
Thesis pillars
- Consistent Earnings Delivery↑Improving
- Strong Financial Health Score→Stable
- Confirmed Technical Downtrend↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Medtronic plc. (MDT) Stock Analysis
Range Bound setup
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $83.21, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole suppliers for certain components; Thin upside margin: 5.8%.
Medtronic is a global healthcare technology company operating four segments — Cardiovascular, Neuroscience, Medical Surgical, and Diabetes — that develop, manufacture and sell device-based medical therapies in more than 150 countries. The company employs over 95,000 full-time... Read more
Hold if already holding. Not a fresh buy at $83.21, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole suppliers for certain components; Thin upside margin: 5.8%. Chart setup: RSI 50 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Score 6.0/10, moderate confidence.
Passes 6/9 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 38d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: moderate.
About Medtronic plc.
About Medtronic plc.
Medtronic's four reportable segments — Cardiovascular, Neuroscience, Medical Surgical, and Diabetes — sell device-based therapies including the Micra leadless pacemaker, Evolut TAVR valves, and the MiniMed 780G insulin pump system to healthcare providers in more than 150 countries. The company employs over 95,000 full-time employees, with 44% based in the U.S. or Puerto Rico, and in May 2025 announced plans to separate the Diabetes Operating Unit into an independent, publicly traded company within 18 months.
Medtronic sells therapeutic and diagnostic devices directly to hospitals, physicians' offices, and ambulatory care centers, with revenue tied to reimbursement approval from healthcare insurers and national tender pricing in markets such as China. Manufacturing spans company-owned facilities worldwide, supplemented by third-party sterilization providers, and the company sources components, raw materials, and services — including some obtained from sole suppliers — from numerous vendors across multiple countries, exposing production to shortages such as the semiconductor and resin constraints noted in the filing. Growth also depends on maintaining working relationships with the healthcare professionals who research, market, and train on new devices, and on integrating acquired technologies without disrupting existing product lines.
Show full overview
Medtronic's supply chain carries concentrated single-source exposure: the 10-K discloses that certain components, raw materials, and services used to manufacture its devices are obtained from sole suppliers, and that several key products are sterilized at a single facility with constrained capacity and no readily available alternate site. Because sterilization and manufacturing facilities require lengthy regulatory approval before a replacement can come online, damage to or closure of one of these sites could halt production of the affected devices faster than a new supplier or sterilizer could be qualified — a risk the company treats as distinct from, and additive to, its broader raw-material cost exposure to resins and petroleum-based inputs.
See also: Healthcare · Medical Devices
From Medtronic plc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-26Recent Developments — Medtronic plc.
Latest news
- NEWS Can Medtronic (MDT) Close the Growth Gap With Its Bigger MedTech Rivals? - Yahoo Finance — Yahoo Finance neutral
- NEWS Can Medtronic (MDT) Close the Growth Gap With Its Bigger MedTech Rivals? - finance.yahoo.com — finance.yahoo.com positive
- NEWS Medtronic plc stock (IE00BTN1Y115): investors eye upcoming Q4 2026 earnings as options market prices - AD HOC NEWS — AD HOC NEWS neutral
- NEWS A Look at Medtronic PLC (MDT) After 3.9% Decline -- GF Value $99 - GuruFocus — GuruFocus negative
- NEWS Medtronic PLC stock underperforms Wednesday when compared to competitors - MarketWatch — MarketWatch negative
Generated 2026-07-26T08:02:04Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSuppliersole suppliers for certain components10-K Item 1A: 'certain components, raw materials and services needed to manufacture our products are obtained from sole suppliers'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $83.21, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole suppliers for certain components; Thin upside margin: 5.8%. Chart setup: RSI 50 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Target $88.06 (+5.8%), stop $78.81 (−5.6%), A.R:R 1.0:1. Score 6.0/10, moderate confidence.
Take-profit target: $88.06 (+5.8% upside). Target $88.06 (+5.8%), stop $78.81 (−5.6%), A.R:R 1.0:1. Stop-loss: $78.81.
Concentration risk — Supplier: sole suppliers for certain components; Thin upside margin: 5.8%; Negative momentum.
Medtronic plc. trades at a P/E of 22.0 (forward 13.0). TrendMatrix value score: 6.4/10. Verdict: Hold.
37 analysts cover MDT with a consensus score of 3.8/5. Average price target: $98.
What does Medtronic plc. do?Medtronic is a global healthcare technology company operating four segments — Cardiovascular, Neuroscience, Medical...
Medtronic is a global healthcare technology company operating four segments — Cardiovascular, Neuroscience, Medical Surgical, and Diabetes — that develop, manufacture and sell device-based medical therapies in more than 150 countries. The company employs over 95,000 full-time employees, 44% based in the U.S. or Puerto Rico, and announced in May 2025 its intention to separate the Diabetes business into a new independent, publicly traded company within about 18 months.